Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Cancer and Gene Therapy Treatment
April 11 2019 - 08:30AM
via NetworkWire — Genprex Inc. (NASDAQ:GNPX) today announces its
placement in an editorial published by NetworkNewsWire ("NNW"), a
multifaceted financial news and publishing company for private and
public entities.
To view the full publication, titled “Potential Blockbuster Gene
Therapy Programs to Watch in 2019,” visit: http://nnw.fm/YC9iq
Perhaps no other disease strikes as much dread and fear as
cancer. Many successful treatments are available today that didn't
exist just a couple decades ago; however, cancer cells and how they
grow remain unpredictable and, in some cases, mysterious. Even
after seemingly effective conventional treatments, cancer cells can
hide out in some patients and resurface. Genprex Inc.
(NASDAQ:GNPX) is pioneering a new approach to treating
cancer.
Genprex’s initial product candidate, Oncoprex, is an immunogene
therapy for non-small cell lung cancer (NSCLC), one of the most
common causes of cancer deaths in the world. About 85% of lung
cancers are non-small cell lung cancer. Survival rates for late
stage non-small cell lung cancer haven’t improved significantly in
over a quarter century. Genprex is in hot pursuit of life-changing
gene technologies for patients facing this dismal outlook.
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company
developing potentially life-changing technologies for cancer
patients, based upon a unique proprietary technology platform,
including Genprex’s initial product candidate, Oncoprex™ immunogene
therapy for non-small cell lung cancer (NSCLC). Genprex’s platform
technologies are designed to administer cancer fighting genes by
encapsulating them into nanoscale hollow spheres called
nanovesicles, which are then administered intravenously and taken
up by tumor cells where they express proteins that are missing or
found in low quantities. Oncoprex has a multimodal mechanism of
action whereby it interrupts cell signaling pathways that cause
replication and proliferation of cancer cells, re-establishes
pathways for apoptosis, or programmed cell death, in cancer cells,
and modulates the immune response against cancer cells. Oncoprex
has also been shown to block mechanisms that create drug
resistance. Visit the company’s web site at www.genprex.com or
follow Genprex on Twitter at twitter.com/genprex, Facebook at
facebook.com/genprexinc, and LinkedIn at
linkedin.com/company/genprex.
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content
distribution company that provides (1) access to a network of wire
services via NetworkWire to reach all target markets,
industries and demographics in the most effective manner possible,
(2) article and editorial syndication to 5,000+ news outlets, (3)
enhanced press release services to ensure maximum impact, (4)
social media distribution via the Investor Brand Network (IBN) to
nearly 2 million followers, (5) a full array of corporate
communications solutions, and (6) a total news coverage solution
with NNW Prime. As a multifaceted organization with an extensive
team of contributing journalists and writers, NNW is uniquely
positioned to best serve private and public companies that desire
to reach a wide audience of investors, consumers, journalists and
the general public. By cutting through the overload of information
in today’s market, NNW brings its clients unparalleled visibility,
recognition and brand awareness. NNW is where news, content and
information converge. For more information, please visit
https://www.NetworkNewsWire.com.
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer.
Forward-Looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended
and Section 21E of the Securities Exchange Act of 1934, as amended.
All forward-looking statements are inherently uncertain as they are
based on current expectations and assumptions concerning future
events or future performance of the company. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which are only predictions and speak only as of the date hereof. In
evaluating such statements, prospective investors should review
carefully various risks and uncertainties identified in this
release and matters set in the company's SEC filings. These risks
and uncertainties could cause the company's actual results to
differ materially from those indicated in the forward-looking
statements.
Corporate Communications:
NetworkWire (NW) New York, New York www.NetworkNewsWire.com
212.418.1217 Office Editor@NetworkWire.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Mar 2023 to Mar 2024